Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients
- PMID: 30584645
- PMCID: PMC6424932
- DOI: 10.1007/s11255-018-2050-3
Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients
Abstract
Purpose: Data concerning the relation between increased levels of circulating sclerostin (a physiological inhibitor of bone formation) and bone turnover in patients with chronic renal failure (CRF) are limited. Therefore, the aim of this study was to evaluate associations between plasma sclerostin levels and calcium-phosphate disturbances, markers of bone turnover as well as inflammation in haemodialysis (HD) patients.
Methods: In plasma samples obtained in 150 stable HD patients (92 men) aged 40-70 years, levels of sclerostin, fibroblast growth factor (cFGF23), osteocalcin, the N-terminal propeptide of type I procollagen, C-terminal telopeptide of the alpha chain of type I collagen (β-CTx), and inflammatory markers (IL-6 and TNF-α) in addition to routine parameters (calcium, phosphorus, parathyroid hormone-iPTH, 25-OH-D, alkaline phosphatase) were measured.
Results: Plasma sclerostin concentrations were significantly higher in HD men than women (2.61 vs. 1.88 ng/mL, p < 0.01). Patients with sclerostin levels above median were characterized by lower iPTH and IL-6, but higher cFGF23 and TNF-α (significantly only in men) concentrations. Plasma sclerostin concentration positively correlated with serum 25-OH-D (τ = 0.204), phosphorus (τ = 0.1482), and TNF-α (τ = 0.183) and inversely with iPTH (τ = - 0.255), alkaline phosphatase (τ = - 0.203), IL-6 (τ =- 0.201), and β-CTx (τ = - 0.099) levels. In multivariate regression analysis, variability of sclerostin levels was explained by sex and 25-OH-D and phosphorus levels.
Conclusions: Increased circulating sclerostin levels seem to reflect slower bone turnover in HD patients. Low levels of sclerostin are associated with vitamin D deficiency and good phosphates alignment.
Keywords: Calcium–phosphate disturbances; Chronic kidney disease-mineral and bone disorder (CKD-MBD); Haemodialysis patients; Renal osteodystrophy (ROD); Sclerostin.
Conflict of interest statement
Conflict of interest
Authors declare that have no conflict of interest.
Ethical approval
All procedures performed were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration with its later amendments.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Figures
Similar articles
-
Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder?Int Urol Nephrol. 2018 Oct;50(10):1863-1870. doi: 10.1007/s11255-018-1935-5. Epub 2018 Jul 20. Int Urol Nephrol. 2018. PMID: 30030677
-
Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD.PLoS One. 2017 May 11;12(5):e0176411. doi: 10.1371/journal.pone.0176411. eCollection 2017. PLoS One. 2017. PMID: 28493902 Free PMC article.
-
The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease .Clin Nephrol. 2020 Feb;93(2):65-76. doi: 10.5414/CN109763. Clin Nephrol. 2020. PMID: 31793871
-
Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation.Kidney Int. 2017 Dec;92(6):1343-1355. doi: 10.1016/j.kint.2017.07.021. Epub 2017 Sep 28. Kidney Int. 2017. PMID: 28964571 Review.
-
Renal osteodystrophy in dialysis patients: diagnosis and treatment.Artif Organs. 1998 Jul;22(7):530-57. doi: 10.1046/j.1525-1594.1998.06198.x. Artif Organs. 1998. PMID: 9684690 Review.
Cited by
-
Sclerostin: a new biomarker of CKD-MBD.Int Urol Nephrol. 2020 Jan;52(1):107-113. doi: 10.1007/s11255-019-02290-3. Epub 2019 Oct 14. Int Urol Nephrol. 2020. PMID: 31612420 Review.
-
Sclerostin Inhibition: A Novel Target for the Treatment of Postmenopausal Osteoporosis.J Midlife Health. 2021 Oct-Dec;12(4):267-275. doi: 10.4103/jmh.JMH_106_20. Epub 2022 Jan 20. J Midlife Health. 2021. PMID: 35264832 Free PMC article. Review.
-
Comparative Analysis of Vascular Calcification Risk Factors in Pre-Hemodialysis and Prevalent Hemodialysis Adult Patients: Insights into Calcification Biomarker Associations and Implications for Intervention Strategies in Chronic Kidney Disease.Diagnostics (Basel). 2024 Apr 17;14(8):824. doi: 10.3390/diagnostics14080824. Diagnostics (Basel). 2024. PMID: 38667470 Free PMC article.
-
Role of sclerostin in mastocytosis bone disease.Sci Rep. 2025 Jan 2;15(1):161. doi: 10.1038/s41598-024-83851-0. Sci Rep. 2025. PMID: 39747949 Free PMC article.
-
Increased Serum Sclerostin Level Is a Risk Factor for Peripheral Artery Disease in Patients with Hypertension.Medicina (Kaunas). 2025 Jul 1;61(7):1204. doi: 10.3390/medicina61071204. Medicina (Kaunas). 2025. PMID: 40731833 Free PMC article.
References
-
- Carvallo L, Henríquez B, Paredes R, et al. 1alpha,25-dihydroxy vitamin D3-enhanced expression of the osteocalcin gene involves increased promoter occupancy of basal transcription regulators and gradual recruitment of the 1-alpha,25-dihydroxy vitamin D3 receptor-SRC-1 coactivator complex. J Cell Physiol. 2008;214:740–749. doi: 10.1002/jcp.21267. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical